Discovery of tryptanthrin derivatives as potent inhibitors of indoleamine 2,3-dioxygenase with therapeutic activity in lewis lung cancer (LLC) tumor-bearing mice

Journal of Medicinal Chemistry

Volumn 56, Issue 21, 2013, Pages 8321-8331

  Yang, Shuangshuang ^a   Li, Xishuai ^a   Hu, Fangfang ^b   Li, Yinlong ^a   Yang, Yunyun ^a   Yan, Junkai ^a   Kuang, Chunxiang ^b   Yang, Qing ^a  

^a FUDAN UNIVERSITY   (China)

^b TONGJI UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

2 FLUORINETRYPTANTHRIN; 8 FLUORINETRYPTANTHRIN; BETA ACTIN; INDOLE DERIVATIVE; INDOLEAMINE 2,3 DIOXYGENASE; INDOLEAMINE 2,3 DIOXYGENASE INHIBITOR; TRANSCRIPTION FACTOR FOXP3; TRYPTANTHRIN DERIVATIVE; TRYPTOPHAN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CONTROLLED STUDY; DRUG MECHANISM; DRUG POTENCY; DRUG SCREENING; DRUG SYNTHESIS; ENZYME INHIBITION; HUMAN; HUMAN CELL; IMMUNOREGULATION; LEWIS CARCINOMA; LYMPHOCYTE PROLIFERATION; MOUSE; NONHUMAN; OXIDATION REDUCTION POTENTIAL; REGULATORY T LYMPHOCYTE; STRUCTURE ACTIVITY RELATION; TUMOR IMMUNITY;

ANIMALS; ANTINEOPLASTIC AGENTS; CARCINOMA, LEWIS LUNG; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG DISCOVERY; ENZYME INHIBITORS; HUMANS; INDOLEAMINE-PYRROLE 2,3,-DIOXYGENASE; LUNG NEOPLASMS; MICE; MOLECULAR STRUCTURE; QUINAZOLINES; STRUCTURE-ACTIVITY RELATIONSHIP; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84887959515     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm401195n     Document Type: Article

References (57)

1. Takikawa, O.; Yoshida, R.; Kido, R.; Hayaishi, O. Tryptophan degradation in mice initiated by indoleamine 2,3-dioxygenase J. Biol. Chem. 1986, 261, 3648-3653
2. Yamazaki, F.; Kuroiwa, T.; Takikawa, O.; Kido, R. Human indolylamine 2,3-dioxygenase. Its tissue distribution, and characterization of the placental enzyme Biochem. J. 1985, 230, 635-638
3. Heyes, M. P.; Saito, K.; Crowley, J. S.; Davis, L. E.; Demitrack, M. A.; Der, M.; Dilling, L. A.; Elia, J.; Kruesi, M. J.; Lackner, A.; Et, A. Quinolinic acid and kynurenine pathway metabolism in inflammatory and non-inflammatory neurological disease Brain 1992, 115 (Part 5) 1249-1273
4. Guillemin, G. J.; Brew, B. J.; Noonan, C. E.; Takikawa, O.; Cullen, K. M. Indoleamine 2,3 dioxygenase and quinolinic acid immunoreactivity in Alzheimer's disease hippocampus Neuropathol. Appl. Neurol. 2005, 31, 395-404
5. Wichers, M. C.; Maes, M. The role of indoleamine 2,3-dioxygenase (IDO) in the pathophysiology of interferon-alpha-induced depression J. Psychiatry Neurosci. 2004, 29, 11-17
6. Sardar, A. M.; Reynolds, G. P. Frontal cortex indoleamine-2,3-dioxygenase activity is increased in HIV-1-associated dementia Neurosci. Lett. 1995, 187, 9-12
7. Munn, D. H.; Mellor, A. L. Indoleamine 2,3-dioxygenase and tumor-induced tolerance J. Clin. Invest. 2007, 117, 1147-1154
8. Uyttenhove, C.; Pilotte, L.; Theate, I.; Stroobant, V.; Colau, D.; Parmentier, N.; Boon, T.; Van den Eynde, B. J. Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase Nat. Med. 2003, 9, 1269-1274
9. Okamoto, A.; Nikaido, T.; Ochiai, K.; Takakura, S.; Saito, M.; Aoki, Y.; Ishii, N.; Yanaihara, N.; Yamada, K.; Takikawa, O.; Kawaguchi, R.; Isonishi, S.; Tanaka, T.; Urashima, M. Indoleamine 2,3-dioxygenase serves as a marker of poor prognosis in gene expression profiles of serous ovarian cancer cells Clin. Cancer Res. 2005, 11, 6030-6039
10. Hou, D. Y.; Muller, A. J.; Sharma, M. D.; DuHadaway, J.; Banerjee, T.; Johnson, M.; Mellor, A. L.; Prendergast, G. C.; Munn, D. H. Inhibition of indoleamine 2,3-dioxygenase in dendritic cells by stereoisomers of 1-methyl-tryptophan correlates with antitumor responses Cancer Res. 2007, 67, 792-801
11. Muller, A. J.; DuHadaway, J. B.; Donover, P. S.; Sutanto-Ward, E.; Prendergast, G. C. Inhibition of indoleamine 2,3-dioxygenase, an immunoregulatory target of the cancer suppression gene Bin1, potentiates cancer chemotherapy Nat. Med. 2005, 11, 312-319
12. Sharma, M. D.; Hou, D. Y.; Liu, Y.; Koni, P. A.; Metz, R.; Chandler, P.; Mellor, A. L.; He, Y.; Munn, D. H. Indoleamine 2,3-dioxygenase controls conversion of Foxp3+ Tregs to TH17-like cells in tumor-draining lymph nodes Blood 2009, 113, 6102-6111
13. Gajewski, T. F.; Meng, Y.; Blank, C.; Brown, I.; Kacha, A.; Kline, J.; Harlin, H. Immune resistance orchestrated by the tumor microenvironment Immunol. Rev. 2006, 213, 131-145
14. Bauer, T. M.; Jiga, L. P.; Chuang, J. J.; Randazzo, M.; Opelz, G.; Terness, P. Studying the immunosuppressive role of indoleamine 2,3-dioxygenase: tryptophan metabolites suppress rat allogeneic T-cell responses in vitro and in vivo Transplant Int. 2005, 18, 95-100
15. Thornton, A. M.; Piccirillo, C. A.; Shevach, E. M. Activation requirements for the induction of CD4+CD25+ T cell suppressor function Eur. J. Immunol. 2004, 34, 366-376
16. Fontenot, J. D.; Gavin, M. A.; Rudensky, A. Y. Foxp3 programs the development and function of CD4+CD25+ regulatory T cells Nat. Immunol. 2003, 4, 330-336
17. Nakamura, T.; Shima, T.; Saeki, A.; Hidaka, T.; Nakashima, A.; Takikawa, O.; Saito, S. Expression of indoleamine 2,3-dioxygenase and the recruitment of Foxp3-expressing regulatory T cells in the development and progression of uterine cervical cancer Cancer Sci. 2007, 98, 874-881
18. Chung, D. J.; Rossi, M.; Romano, E.; Ghith, J.; Yuan, J.; Munn, D. H.; Young, J. W. Indoleamine 2,3-dioxygenase-expressing mature human monocyte-derived dendritic cells expand potent autologous regulatory T cells Blood 2009, 114, 555-563
19. Sharma, M. D.; Baban, B.; Chandler, P.; Hou, D. Y.; Singh, N.; Yagita, H.; Azuma, M.; Blazar, B. R.; Mellor, A. L.; Munn, D. H. Plasmacytoid dendritic cells from mouse tumor-draining lymph nodes directly activate mature Tregs via indoleamine 2,3-dioxygenase J. Clin. Invest. 2007, 117, 2570-2582
20. Vottero, E.; Balgi, A.; Woods, K.; Tugendreich, S.; Melese, T.; Andersen, R. J.; Mauk, A. G.; Roberge, M. Inhibitors of human indoleamine 2,3-dioxygenase identified with a target-based screen in yeast Biotechnol. J. 2006, 1, 282-288
21. 2 incorporation by a heme-containing dioxygenase Proc. Natl. Acad. Sci. U.S.A. 2006, 103, 2611-2616
22. Carr, G.; Tay, W.; Bottriell, H.; Andersen, S. K.; Mauk, A. G.; Andersen, R. J. Plectosphaeroic acids A, B, and C, indoleamine 2,3-dioxygenase inhibitors produced in culture by a marine isolate of the fungus Plectosphaerella cucumerina Org. Lett. 2009, 11, 2996-2999
23. Yue, E. W.; Douty, B.; Wayland, B.; Bower, M.; Liu, X.; Leffet, L.; Wang, Q.; Bowman, K. J.; Hansbury, M. J.; Liu, C.; Wei, M.; Li, Y.; Wynn, R.; Burn, T. C.; Koblish, H. K.; Fridman, J. S.; Metcalf, B.; Scherle, P. A.; Combs, A. P. Discovery of potent competitive inhibitors of indoleamine 2,3-dioxygenase with in vivo pharmacodynamic activity and efficacy in a mouse melanoma model J. Med. Chem. 2009, 52, 7364-7367
24. Gaspari, P.; Banerjee, T.; Malachowski, W. P. Structure-activity study of brassinin derivatives as indoleamine 2,3-dioxygenase inhibitors J. Med. Chem. 2006, 49, 684-692
25. Kumar, S.; Jaller, D.; Patel, B.; LaLonde, J. M.; DuHadaway, J. B.; Malachowski, W. P.; Prendergast, G. C.; Muller, A. J. Structure based development of phenylimidazole-derived inhibitors of indoleamine 2,3-dioxygenase J. Med. Chem. 2008, 51, 4968-4977
26. Rohrig, U. F.; Awad, L.; Grosdidier, A.; Larrieu, P.; Stroobant, V.; Colau, D.; Cerundolo, V.; Simpson, A. J.; Vogel, P.; Van den Eynde, B. J.; Zoete, V.; Michielin, O. Rational design of indoleamine 2,3-dioxygenase inhibitors J. Med. Chem. 2010, 53, 1172-1189
27. John, S.; Thangapandian, S.; Sakkiah, S.; Lee, K. W. Identification of potent virtual leads to design novel indoleamine 2,3-dioxygenase inhibitors: pharmacophore modeling and molecular docking studies Eur. J. Med. Chem. 2010, 45, 4004
28. Honda, G.; Tabata, M.; Tsuda, M. The antimicrobial specificity of tryptanthrin Planta Med. 1979, 37, 172-174
29. Mitscher, L. A.; Baker, W. Tuberculosis: a search for novel therapy starting with natural products Med. Res. Rev. 1998, 18, 363-374
30. Takei, Y.; Kunikata, T.; Aga, M.; Inoue, S.; Ushio, S.; Iwaki, K.; Ikeda, M.; Kurimoto, M. Tryptanthrin inhibits interferon-gamma production by Peyer's patch lymphocytes derived from mice that had been orally administered staphylococcal enterotoxin Biol. Pharm. Bull. 2003, 26, 365-367
31. Recio, M. C.; Cerda-Nicolas, M.; Potterat, O.; Hamburger, M.; Rios, J. L. Anti-inflammatory and antiallergic activity in vivo of lipophilic Isatis tinctoria extracts and tryptanthrin Planta Med. 2006, 72, 539-546
32. Kimoto, T.; Yamamoto, Y.; Hino, K.; Koya, S.; Aga, H.; Hashimoto, T.; Hanaya, T.; Arai, S.; Ikeda, M.; Fukuda, S.; Kurimoto, M. Cytotoxic effects of substances in indigo plant (Polygonum tinctorium Lour.) on malignant tumor cells Nat. Med. 1999, 53, 72-79
33. Bhattacharjee, A. K.; Skanchy, D. J.; Jennings, B.; Hudson, T. H.; Brendle, J. J.; Werbovetz, K. A. Analysis of stereoelectronic properties, mechanism of action and pharmacophore of synthetic indolo[2,1- b ]quinazoline-6,12-dione derivatives in relation to antileishmanial activity using quantum chemical, cyclic voltammetry and 3-D-QSAR CATALYST procedures Bioorg. Med. Chem. 2002, 10, 1979-1989
34. Sugai, A.; Matsumoto, S.; Akiba, N.; Watanabe, Y.; Kawaguchi, H. Tryptanthrin Derivatives Suitable for Electron Transporting Agents and Highly Sensitive Electronic Photographic Photoconductors Using the Same. JP Patent 09095621, 1997.
35. Yu, S. T.; Chern, J. W.; Chen, T. M.; Chiu, Y. F.; Chen, H. T.; Chen, R. H. Cytotoxicity and reversal of multidrug resistance by tryptanthrin-derived indoloquinazolines Acta Pharmacol. Sin. 2010, 31, 259-264
36. Kimoto, T.; Hino, K.; Koya-Miyata, S.; Yamamoto, Y.; Takeuchi, M.; Nishizaki, Y.; Micallef, M. J.; Ushio, S.; Iwaki, K.; Ikeda, M.; Kurimoto, M. Cell differentiation and apoptosis of monocytic and promyelocytic leukemia cells (U-937 and HL-60) by tryptanthrin, an active ingredient of Polygonum tinctorium Lour Pathol. Int. 2001, 51, 315-325
37. Sharma, V. M.; Prasanna, P.; Seshu, K. V.; Renuka, B.; Rao, C. V.; Kumar, G. S.; Narasimhulu, C. P.; Babu, P. A.; Puranik, R. C.; Subramanyam, D.; Venkateswarlu, A.; Rajagopal, S.; Kumar, K. B.; Rao, C. S.; Mamidi, N. V.; Deevi, D. S.; Ajaykumar, R.; Rajagopalan, R. Novel indolo[2,1- b ]quinazoline analogues as cytostatic agents: synthesis, biological evaluation and structure-activity relationship Bioorg. Med. Chem. Lett. 2002, 12, 2303-2307
38. Koya-Miyata, S.; Kimoto, T.; Micallef, M. J.; Hino, K.; Taniguchi, M.; Ushio, S.; Iwaki, K.; Ikeda, M.; Kurimoto, M. Prevention of azoxymethane-induced intestinal tumors by a crude ethyl acetate-extract and tryptanthrin extracted from Polygonum tinctorium Lour Anticancer Res. 2001, 21, 3295-3300
39. Schrenk, D.; Riebniger, D.; Till, M.; Vetter, S.; Fiedler, H. Tryptanthrins: a novel class of agonists of the aryl hydrocarbon receptor Biochem. Pharmacol. 1997, 54, 165-171
40. Motoki, T.; Takami, Y.; Yagi, Y.; Tai, A.; Yamamoto, I.; Gohda, E. Inhibition of hepatocyte growth factor induction in human dermal fibroblasts by tryptanthrin Biol. Pharm. Bull. 2005, 28, 260-266
41. Baker, W. R.; Mitscher, L. A. Indolo[2,1-biquinazoline-6,12-dione Antibacterial Compounds and Methods of Use Thereof. U.S. Patent 5,441,955, 1995.
42. Bergman, J.; Tilstam, U.; Törnroos, K.-W. Reduction and stereochemical studies through n.m.r. and X-ray techniques of indolo[2,1- b ]quinazolines J. Chem. Soc., Perkin Trans. 1 1987, 519-527
43. Kuang, C.; Wang, Y.; Wang, S.; Chen, B.; Guan, Y.; Liu, Y.; Tian, N. Preparation of 5-Halo-4-aryl-1 H -1,2,3-triazoles. CN Patent. Appl. No. 200910054881, 1995.
44. Huang, Q.; Zheng, M.; Yang, S.; Kuang, C.; Yu, C.; Yang, Q. Structure-activity relationship and enzyme kinetic studies on 4-aryl-1 H -1,2,3-triazoles as indoleamine 2,3-dioxygenase (IDO) inhibitors Eur. J. Med. Chem. 2011, 46, 5680-5687
45. Cornish-Bowden, A. A simple graphical method for determining the inhibition constants of mixed, uncompetitive and non-competitive inhibitors Biochem. J. 1974, 137, 143-144
46. Friberg, M.; Jennings, R.; Alsarraj, M.; Dessureault, S.; Cantor, A.; Extermann, M.; Mellor, A. L.; Munn, D. H.; Antonia, S. J. Indoleamine 2,3-dioxygenase contributes to tumor cell evasion of T cell-mediated rejection Int. J. Cancer 2002, 101, 151-155
47. Huang, A.; Fuchs, D.; Widner, B.; Glover, C.; Henderson, D. C.; Allen-Mersh, T. G. Serum tryptophan decrease correlates with immune activation and impaired quality of life in colorectal cancer Br. J. Cancer 2002, 86, 1691-1696
48. Weinlich, G.; Murr, C.; Richardsen, L.; Winkler, C.; Fuchs, D. Decreased serum tryptophan concentration predicts poor prognosis in malignant melanoma patients Dermatology 2007, 214, 8-14
49. Corm, S.; Berthon, C.; Imbenotte, M.; Biggio, V.; Lhermitte, M.; Dupont, C.; Briche, I.; Quesnel, B. Indoleamine 2,3-dioxygenase activity of acute myeloid leukemia cells can be measured from patients' sera by HPLC and is inducible by IFN-gamma Leuk. Res. 2009, 33, 490-494
50. Opitz, C. A.; Litzenburger, U. M.; Opitz, U.; Sahm, F.; Ochs, K.; Lutz, C.; Wick, W.; Platten, M. The indoleamine-2,3-dioxygenase (IDO) inhibitor 1-methyl- d -tryptophan upregulates IDO1 in human cancer cells PLoS One 2011, 6, e19823
51. Boasso, A.; Vaccari, M.; Fuchs, D.; Hardy, A. W.; Tsai, W. P.; Tryniszewska, E.; Shearer, G. M.; Franchini, G. Combined effect of antiretroviral therapy and blockade of IDO in SIV-infected rhesus macaques J. Immunol. 2009, 182, 4313-4320
52. Liu, X.; Shin, N.; Koblish, H. K.; Yang, G.; Wang, Q.; Wang, K.; Leffet, L.; Hansbury, M. J.; Thomas, B.; Rupar, M.; Waeltz, P.; Bowman, K. J.; Polam, P.; Sparks, R. B.; Yue, E. W.; Li, Y.; Wynn, R.; Fridman, J. S.; Burn, T. C.; Combs, A. P.; Newton, R. C.; Scherle, P. A. Selective inhibition of IDO1 effectively regulates mediators of antitumor immunity Blood 2010, 115, 3520-3530
53. Fallarino, F.; Grohmann, U.; You, S.; McGrath, B. C.; Cavener, D. R.; Vacca, C.; Orabona, C.; Bianchi, R.; Belladonna, M. L.; Volpi, C.; Santamaria, P.; Fioretti, M. C.; Puccetti, P. The combined effects of tryptophan starvation and tryptophan catabolites down-regulate T cell receptor zeta-chain and induce a regulatory phenotype in naive T cells J. Immunol. 2006, 176, 6752-6761
54. Hori, S.; Nomura, T.; Sakaguchi, S. Control of regulatory T cell development by the transcription factor Foxp3 Science 2003, 299, 1057-1061
55. Munn, D. H.; Sharma, M. D.; Hou, D.; Baban, B.; Lee, J. R.; Antonia, S. J.; Messina, J. L.; Chandler, P.; Koni, P. A.; Mellor, A. L. Expression of indoleamine 2,3-dioxygenase by plasmacytoid dendritic cells in tumor-draining lymph nodes J. Clin. Invest. 2004, 114, 280-290
56. Yu, C. J.; Zheng, M. F.; Kuang, C. X.; Huang, W. D.; Yang, Q. Oren-gedoku-to and its constituents with therapeutic potential in Alzheimer's disease inhibit indoleamine 2,3-dioxygenase activity in vitro J. Alzheimer's Dis. 2010, 22, 257-266
57. Pergola, C.; Jazzar, B.; Rossi, A.; Northoff, H.; Hamburger, M.; Sautebin, L.; Werz, O. On the inhibition of 5-lipoxygenase product formation by tryptanthrin: mechanistic studies and efficacy in vivo Br. J. Pharmacol. 2012, 165, 765-776